Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Share-based Compensation (2017 - 2025)

Aclaris Therapeutics has reported Share-based Compensation over the past 9 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $2.9 million for Q4 2025, up 2.31% from a year ago — trailing twelve months through Dec 2025 was $12.4 million (up 14.08% YoY), and the annual figure for FY2025 was $12.4 million, up 14.08%.
  • Share-based Compensation for Q4 2025 was $2.9 million at Aclaris Therapeutics, up from $2.9 million in the prior quarter.
  • Over the last five years, Share-based Compensation for ACRS hit a ceiling of $6.8 million in Q1 2023 and a floor of $1.3 million in Q4 2023.
  • Median Share-based Compensation over the past 5 years was $3.6 million (2022), compared with a mean of $3.7 million.
  • Peak annual rise in Share-based Compensation hit 190.11% in 2023, while the deepest fall reached 73.7% in 2023.
  • Aclaris Therapeutics' Share-based Compensation stood at $3.9 million in 2021, then increased by 24.98% to $4.8 million in 2022, then tumbled by 73.7% to $1.3 million in 2023, then surged by 125.91% to $2.9 million in 2024, then increased by 2.31% to $2.9 million in 2025.
  • The last three reported values for Share-based Compensation were $2.9 million (Q4 2025), $2.9 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.